{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:13:50Z","timestamp":1792721630566,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.jaip.2013.01.011","type":"journal-article","created":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T14:52:19Z","timestamp":1361890339000},"page":"163-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Reassessment of Omalizumab-Dosing Strategies and Pharmacodynamics in Inner-City Children and Adolescents"],"prefix":"10.1016","volume":"1","author":[{"given":"Christine A.","family":"Sorkness","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy J.","family":"Wildfire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Calatroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman E.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George T.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Pongracic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meyer","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Teach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Gergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley J.","family":"Szefler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2013.01.011_bib1","unstructured":"National Heart, Lung, and Blood Institute. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma Full Report 2007. August 28, 2007. Available from: www.nhlbi.nih.gov\/guidelines\/asthma\/asthgdln.htm. Accessed December 1, 2011."},{"key":"10.1016\/j.jaip.2013.01.011_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2013.01.011_bib3","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1164\/ajrccm.155.6.9196082","article-title":"The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects","volume":"155","author":"Fahy","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2013.01.011_bib4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2222.2005.02191.x","article-title":"Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy","volume":"35","author":"Holgate","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2013.01.011_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2013.01.011_bib6","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2013.01.011_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Soler","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2013.01.011_bib8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaci.2004.12.006","article-title":"Inner City Asthma Study: relationships among sensitivity, allergen exposure, and asthma morbidity","volume":"115","author":"Gruchalla","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2013.01.011_bib9","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/j.1398-9995.2010.02412.x","article-title":"Allergen-specific IgE as a biomarker of exposure plus sensitization in inner-city adolescents with asthma","volume":"65","author":"Matsui","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2013.01.011_bib10","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJM199705083361904","article-title":"The\u00a0role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma","volume":"336","author":"Rosenstreich","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2013.01.011_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaci.2010.01.023","article-title":"Pest and allergen exposure and abatement in inner-city asthma: a work group report of the American Academy of Allergy, Asthma & Immunology Indoor Allergy\/Air Pollution Committee","volume":"125","author":"Sheehan","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2013.01.011_bib12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2013.01.011_bib13","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1542\/peds.108.2.e36","article-title":"Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)","volume":"108","author":"Milgrom","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2013.01.011_bib14","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJMoa032097","article-title":"Results of a home-based environmental intervention among urban children with asthma","volume":"351","author":"Morgan","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2013.01.011_bib15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0140-6736(08)61448-8","article-title":"Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial","volume":"372","author":"Szefler","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2013.01.011_bib16","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2013.01.011_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1745-6215-10-43","article-title":"Dealing with heterogeneity of treatment effects: is the literature up to the challenge?","volume":"10","author":"Gabler","year":"2009","journal-title":"Trials"},{"key":"10.1016\/j.jaip.2013.01.011_bib18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.rmed.2009.03.008","article-title":"The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update","volume":"103","author":"Holgate","year":"2009","journal-title":"Respir Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219813000871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219813000871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:05:04Z","timestamp":1761973504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219813000871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S2213219813000871"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2013.01.011","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reassessment of Omalizumab-Dosing Strategies and Pharmacodynamics in Inner-City Children and Adolescents","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2013.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}